SER-155
Prevention of antibiotic-resistant infections and graft-versus-host disease (GvHD) in immunocompromised patients
Key Facts
About Seres Therapeutics
Seres Therapeutics is a trailblazer in the microbiome field, with a mission to transform patient lives by restoring microbiome health. Its landmark achievement is the FDA approval and commercialization of VOWST™ for recurrent C. difficile infection, validating its platform and establishing a first-mover advantage. The company's strategy involves leveraging this platform to expand into larger gastrointestinal and immunology indications, while navigating the challenges of commercial execution, pipeline development, and financial sustainability.
View full company profileAbout Seres Therapeutics
Seres Therapeutics is a trailblazer in the microbiome field, with a mission to transform patient lives by restoring microbiome health. Its landmark achievement is the FDA approval and commercialization of VOWST™ for recurrent C. difficile infection, validating its platform and establishing a first-mover advantage. The company's strategy involves leveraging this platform to expand into larger gastrointestinal and immunology indications, while navigating the challenges of commercial execution, pipeline development, and financial sustainability.
View full company profile